Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene’s $20 million boost and cancer trial updates

(7:42)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Imugene Limited (ASX:IMU) Three Complete Responses in Azer-Cel Phase 1b Trial

(3:51)

Imugene Science Series With Dr Yuman Fong - November 2024

(20:20)

Imugene expands CAR T-Cell and Oncolytic Virotherapy trials in Australia and the US

(5:25)

Imugene (ASX:IMU) | JMM \u0026 éthica Capital Innovation Interview \\ May 2024

(5:4)

Imugene begins VAXINIA trial for bile tract cancer

(10:)

Developing Cancer Cures through the ASX | Going Public w Leslie Chong \u0026 Paul Hopper

(53:26)

Imugene (ASX:IMU) | JMM \u0026 éthica Capital Innovation \u0026 Investment Insights | May 2024

(15:6)

Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO

(7:40)

Imugene Investor Presentation | Non-deal Roadshow 2023 Australia

(44:28)

Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

(20:11)

Imugene steps up dosage at groundbreaking VAXINIA cancer trial

(19:3)

'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

(4:51)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Imugene achieves ‘complete response’ with mid dose cancer trial

(7:36)

Imugene Investor Webinar: MAST Study Update

(27:13)

Imugene CEO And COO Speak With JustStocks Video After Promising Results In Blood Cancer Trial

(7:17)

ASX Small and Mid-Cap Conference March 2024 | Imugene Ltd (ASX:IMU)

(20:44)

Imugene MAST trial delivers two-year complete response in bile tract cancer patient

(4:54)

Imugene PD1 Vaxx 1080p

(4:27)

7 News Australia | Australian company Imugene; saving lives using a cancer eating virus

(2:18)

Imugene featured on Behind The Scenes with Host Laurence Fishburne.

(5:15)

Meet Garrett Gincley, Vice President of Cell Therapy, External Manufacturing, and Imugene Quality.

(56)

Imugene forges development path of immunotherapies and cancer-killing virus

(24:2)

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

(5:34)

Imugene thrilled as first patient dosed in Phase 1 OASIS trial

(2:30)

Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA

(1:58)